CD47与乳腺癌相关性的研究进展  

Research advances in the relationship between CD47 and breast cancer

作　　者：袁静萍[1] 陈创[2] 高利昆[1] 饶洁[1] 吴昊[1] 阎红琳 

机构地区：[1]武汉大学人民医院病理科,武汉430060 [2]武汉大学人民医院乳腺甲状腺外科,武汉430060

出　　处：《中国组织化学与细胞化学杂志》2016年第4期371-374,共4页Chinese Journal of Histochemistry and Cytochemistry

基　　金：国家自然科学基金(31600866);武汉大学自主科研项目(2042016kf0116)

摘　　要：乳腺癌的发生、发展与许多因素有关,其中免疫系统在其发生与发展过程中发挥重要作用。CD47是高表达于乳腺癌细胞表面的跨膜蛋白,其配体为凝血酶敏感蛋白-1(thrombospondin-1,TSP1)和信号调节蛋白α(signal-regulatory protein alpha,SIRPα),其中CD47/SIRPα信号通路可产生抑制性信号降低巨噬细胞的吞噬作用,产生免疫逃逸。在乳腺癌细胞中CD47表达上调,且高表达的CD47提示预后不良。采用抗CD47抗体可以阻断肿瘤细胞CD47/SIRPα通路介导的抑制吞噬作用,目前抗CD47单克隆抗体的免疫疗法正逐步走向临床试验。本文主要阐述CD47的结构、生理功能及其与肿瘤相关巨噬细胞的关系,并对CD47在乳腺癌中的表达及与预后的关系、在免疫治疗中的作用进行综述。The occurrence and development of breast cancer involves many factors, in which the immune system plays an im-portant role. CD47 is a transmembrane protein abundantly expressed in breast cancer cell surface, its ligands including throm- bospondin-1 （TSP1） and signal-regulatory protein alpha （SIRPa） . The CD47/SIRPa signaling pathway can produce inhibitory signals to reduce macrophage phagocytosis and induce immune escape. Up-regulation of CD47 expression was detected in breast cancer cells, and the high expression of CD47 indicated poor prognosis. Anti-CD47 antibodies can block the inhibition of phagocytosis mediated by GD47/SIRPa pathway in tumor cells. Cucrently, immunotherapy based on anti-CD47 monoclonal antibodies is gradually tested in clini-cal trials. This paper mainly demonstrates the structure and physiological functions of GD47 and its relationship with tumor associated macrophages, and reviews the expression of CD47 in breast cancer and its role in the prognosis and immunotherapy.

关 键 词：CD47 乳腺癌 巨噬细胞 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]